Skip to content

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Oct 2, 2026

Data as of Oct 16

▼ SELL$467K1,535 shares at $304.52Andrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc
Watch LGND
Traded
Oct 2, 2026
Disclosed
Oct 6, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Oct 2, 2026TRADEDDISCLOSED
LGNDSimilar stocks (XLV — its sector index fund), rebased to LGND's price on the disclosure day
LGND since disclosure
−0.5%
after the sale
Similar stocks (XLV) since disclosure
+5.8%
XLV — its sector index fund

Change in closing price from Oct 6, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$600Kdisclosed Oct 6 · filed 4 days after the trade
  2. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$124Kdisclosed Oct 6 · filed 4 days after the trade
  3. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$5.2Kdisclosed Oct 6 · filed 4 days after the trade
  4. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$72.2Kdisclosed Oct 6 · filed 4 days after the trade
  5. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$252Kdisclosed Oct 6 · filed 4 days after the trade

See every trade on LGND →